Psychedelics could be one of the most rewarding opportunities of 2021 and beyond. All as countless studies show how useful they can be in treating mental health issues, such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, and anxiety.
Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression, for example. New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. That’s all game-changing news for companies such as NeonMind Biosciences (CSE:NEON)(OTC:NMDBF),Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Mind Medicine Inc. (NEO:MMED)(NASDAQ:MNMD), Field Trip Health Ltd. (TSX:FTRP) (NASDAQ:FTRP), and Numinus Wellness Inc. (TSXVLNUMI)(OTC:LKYSF).
In addition, according to The Guardian, “Increasing numbers of trials have reported steady doses of dazzlingly promising results for people with a risk of psychological issues. A study in the Lancet last year found that a high dose of psilocybin significantly reduces depressive syndromes and markedly improves anxiety for sustained periods. This appears to be due to the fostering of stronger communication between usually disconnected parts of the brain, engendering a higher state of consciousness as people are less constrained and more able to process emotions.”